Abstract
The Treat-to-Target (T2T) principle has been advocated in a number of inflammatory and non-inflammatory medical illnesses. Tight control of disease activity has been shown to improve the outcome of rheumatoid arthritis and psoriatic arthritis as compared to the conventional approach. However, whether T2T can be applied to patients with lupus nephritis is still under emerging discussion. Treatment of lupus nephritis should target at inducing and maintaining remission of the kidney inflammation so as to preserve renal function and improve survival in the longterm. However, there is no universal agreement on the definition of remission or low disease activity state of nephritis, as well as the time points for switching of therapies. Moreover, despite the availability of objective parameters for monitoring such as proteinuria and urinary sediments, differentiation between ongoing activity and damage in some patients with persistent urinary abnormalities remains difficult without a renal biopsy. A large number of serum and urinary biomarkers have been tested in lupus nephritis but none of them have been validated for routine clinical use. In real life practice, therapeutic options for lupus nephritis are limited. As patients with lupus nephritis are more prone to infective complications, tight disease control with aggressive immunosuppressive therapies may have safety concern. Not until the feasibility, efficacy, safety and cost-effectiveness of T2T in lupus nephritis is confirmed by comparative trials, this approach should not be routinely recommended with the current treatment armamentarium and monitoring regimes.
Keywords: Lupus nephritis, treat-to-target, outcome, immunosuppressive, biomarkers, clinical practice.
Graphical Abstract
[1]
Mok CC. Understanding lupus nephritis: Diagnosis, management, and treatment options. Int J Womens Health 2012; 4: 213-22.
[2]
Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-82.
[3]
Bastian HM, Roseman JM, McGwin G Jr, et al. LUMINA Study Group. Lupus in minority populations: Nature vs nurture. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11: 152-60.
[4]
Fernández M, Alarcón GS, Calvo-Alén J, et al. LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57: 576-84.
[5]
Sánchez E, Rasmussen A, Riba L, et al. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum 2012; 64: 3687-94.
[6]
Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol 2016; 12: 221-34.
[7]
Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 4: 11-7.
[8]
Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013; 65: 2154-60.
[9]
Jolly M, Toloza S, Goker B, et al. Disease-specific quality of life in patients with lupus nephritis. Lupus 2018; 27: 257-64.
[10]
Hahn BH, McMahon MA, Wilkinson A, et al. American College of rheumatology. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
[11]
Bertsias GK, Tektonidou M, Amoura Z, et al. European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
[12]
Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) 2014; 19: 11-20.
[13]
Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up. Ann Rheum Dis 2016; 75: 30-6.
[14]
Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: A randomized trial. Ann Intern Med 2015; 162: 18-26.
[15]
Mok CC, To CH, Yu KL, Ho LY. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study. Lupus 2013; 22: 1135-41.
[16]
Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28: 106-11.
[17]
Díaz-Lagares C, Croca S, Sangle S, et al. UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-64.
[18]
Terrier B, Amoura Z, Ravaud P, et al. Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458-66.
[19]
Rovin BH, Furie R, Latinis K, et al. LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
[20]
Mok CC. Biological and targeted therapies of systemic lupus erythematosus: Evidence and the state of the art. Expert Rev Clin Immunol 2017; 13: 677-92.
[21]
Mok CC. Emerging biological therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2014; 19: 303-22.
[22]
Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol 2018; 70: 266-76.
[23]
Furie R, Khamashta M, Merrill JT, et al. CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017; 69: 376-86.
[24]
Mok CC. Treat-to-target in systemic lupus erythematosus: Are we there yet? Expert Rev Clin Pharmacol 2016; 9: 675-80.
[25]
Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 11: CD008143.
[26]
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
[27]
van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-67.
[28]
van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554-61.
[29]
Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis 2015; 74: 2117-22.
[30]
Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615-21.
[31]
ACCESS trial group. Treatment of lupus nephritis with abatacept: The abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 2014; 66: 3096-104.
[32]
Liang MH, Schur PH, Fortin P, et al. The american college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-32.
[33]
Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015; 67: 1305-13.
[34]
Mok CC, Ho LY, To CH, Chan KL. Factors associated with renal remission, relapse and long-term renal function decline in lupus nephritis treated with combined prednisolone and mycophenolate mofetil or tacrolimus. [abstract]. Arthritis Rheumatol 2015; 67(Suppl. 10): 1292-3.
[35]
Lertdumrongluk P, Somparn P, Kittanamongkolchai W, et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010; 78: 389-95.
[36]
Neumann I, Fuhrmann H, Fang IF, et al. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008; 23: 3514-20.
[37]
Zahr N, Arnaud L, Marquet P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum 2010; 62: 2047-54.
[38]
Djabarouti S, Breilh D, Duffau P, et al. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: An observational cohort study. Arthritis Res Ther 2010; 12: R217.
[39]
Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: Emerging evidence supporting multiple beneficial effects. Intern Med J 2012; 42: 968-78.
[40]
Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum 2013; 43: 264-72.
[41]
Pons-Estel GJ, Alarcón GS, McGwin G Jr, et al. Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61: 830-9.
[42]
Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 2008; 17: 281-8.
[43]
Alarcón GS, McGwin G, Bertoli AM, et al. LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: Data from LUMINA, a multiethnic US cohort (LUMINA). Ann Rheum Dis 2007; 66: 1168-72.
Related Books
Natural Products for the Management of Arthritic Disorders
Article Metrics
82
5
1